ClinicalTrials.gg
RecruitingNCT07170358RIXUpdated Sep 9, 2026

Screening of Biomarkers and Related Mechanisms for RIX

An observational study in Xerostomia Due to Radiotherapy (Disorder), sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 172 studies in Head and Neck Neoplasms with a site in China — 85 open to participants now, 95 under way, 12 of them phase 3. Head and Neck Neoplasms · China.

Planned enrollment
17th of 28
50 · median 110
Started
2024
with 23 others
Observational
28 of 172
17 open now
Primary completion
2026-12
later than 40 of 94 live
Registered
135th of 172
by date

Among the 172 studies in Head and Neck Neoplasms with a site in China, this one is the 17th largest by planned enrollment of the 28 observational ones that give a count, is one of 24 that started in 2024, is one of 28 observational ones, reaches primary completion later than 40 of the 94 other live ones, and was the 135th registered.

Head and Neck Neoplasms

2,713 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

85 of the 172 studies in Head and Neck Neoplasms with a site in China are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Head and Neck Neoplasms with a site in China, or all of them as a file.
02

Study summary

A large number of patients undergoing radiotherapy and chemotherapy are suffering from dry mouth. Due to reduced saliva secretion, patients may experience symptoms such as difficulty chewing and swallowing. In severe cases, they may also experience pain and burning sensation in the oral mucosa, decreased taste, ulcers, which seriously affect the quality of life of patients. However, radiation-induced dry mouth lacks early objective predictive indicators (molecular biomarkers) and the mechanism is unclear. Only when patients experience clinical symptoms will symptomatic treatment be taken to alleviate them. Therefore, elucidating the mechanism of radiation-induced dry mouth syndrome (RIX) and achieving early prediction, detection, and intervention of RIX are crucial in improving the prognosis and quality of life of radiotherapy patients. It is urgent to seek early and precise detection targets in clinical practice to predict dry mouth caused by irreversible damage to salivary gland tissue. This study aims to collect blood samples from patients with severe dry mouth before and after radiotherapy and chemotherapy in clinical practice. Multiple omics techniques will be used to search for predictive molecular biomarkers for RIX, construct a predictive model, and verify the sensitivity and specificity of the biomarkers. The goal is to predict the occurrence of RIX early in clinical practice, intervene in advance, greatly improve the prognosis of radiotherapy and chemotherapy patients, and enhance their quality of life.

03

Conditions studied

  • Xerostomia Due to Radiotherapy (Disorder)

Keywords

  • Head and neck tumor
  • radiotherapy
  • biomarkers
  • xerostomia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Head and neck cancer radiotherapy patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of head and neck cancer;
  • Plan to undergo curative treatment with radiotherapy alone or in combination with synchronous chemotherapy, immunotherapy, or targeted therapy;
  • Age greater than or equal to 18 years old, Fully understand the purpose and significance of this study, voluntarily participate and sign an form.

Exclusion criteria

Exclusion Criteria:

  • diseases;
  • History of head and neck radiotherapy;
  • Severe dry mouth before radiotherapy;
  • Suffering from advanced chronic diseases: heart failure - functional classification III/IV, renal failure - estimated under 30mL/min/1.73m2, liver failure - score C or D.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • No xerostomia before radiotherapy

    Resting saliva flow rate greater than 1ml/10min before radiotherapy

  • Mild xerostomia during radiotherapy

    During radiotherapy, a resting saliva flow rate between 0.5ml/10min-1ml/10min is considered mild dry mouth

    Radiation: Radiation Therapy

  • Moderate to severe xerostomia during radiotherapy

    A resting saliva flow rate below 0.5ml/10min during radiotherapy is considered moderate to severe xerostomia

    Radiation: Radiation Therapy

  • Mild xerostomia after radiotherapy

    After radiotherapy, a resting saliva flow rate between 0.5ml/10min-1ml/10min is considered mild dry mouth

    Radiation: Radiation Therapy

  • Moderate to severe xerostomia xerostomia after radiotherapy

    A resting saliva flow rate below 0.5ml/10min after radiotherapy is considered moderate to severe xerostomia

    Radiation: Radiation Therapy

Interventions

  • RadiationRadiation Therapy

    Radiotherapy for Head and Neck Cancer Patients

06

What researchers measure

Primary outcomes

  1. Resting saliva flow measurement

    When fasting in the morning, instruct the patient to gather saliva at the bottom of the mouth, lower their head and slightly open their mouth to allow the gathered saliva to naturally flow into the oral cup. Generally, collect for 10 minutes, with less than 1ml indicating mild dry mouth, less than 0.5ml indicating moderate dry mouth, and less than 0.1ml indicating severe dry mouth.

    Time frame: From the start of radiotherapy to 3 months after completion

Secondary outcomes

  1. Changes in Quality of Life and xerostomia Questionnaire Scores

    According to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-head and neck35(EORTC QLQ-H\&N35) questionnaire, dry mouth symptoms were scored and classified in patients with postoperative oral dryness after radiotherapy.In the dry mouth category, responses of "quite a bit" and "very much" and a total score difference of ≥ 10 points before and after treatment are defined as moderate to severe dry mouth.The higher the overall score, the worse the situation.

    Time frame: From the start of radiotherapy to 3 months after completion

  2. Comparison of Body Mass Index

    Measure the weight changes of patients before and after radiotherapy, weight and height will be combined to report BMI in kg/m\^2.

    Time frame: From the start of radiotherapy to 3 months after completion

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 215 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 144. This study's planned 30 months is below that.

Counting every sponsor, half of 237 studies reached it within 71 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 12, 2025
StartActual
May 17, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 30, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07170358
Collaborators
The Tumor Hospital of Jiangsu Province, The First Affiliated Hospital with Nanjing Medical University, Jinling Hospital Affiliated to Nanjing University School of Medicine
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
May 17, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Lei Jin
Contact
ljin666666@zju.edu.cn
86+13868063666

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion